Corona Remedies Begins Additional Production at Bhayla Facility
Filing Summary
Corona Remedies Ltd has commenced additional commercial production of tablets and capsules at its Bhayla manufacturing facility. The production began on December 22, 2025, increasing the facility’s installed capacity by 400 million units and available capacity by 240 million units. The facility’s existing capacity utilization was 93.58% as of March 31, 2025. The expansion is funded entirely through internal accruals. This update is in accordance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
Corona Remedies Ltd has announced the commencement of additional commercial production at its Bhayla manufacturing facility. The production started on December 22, 2025, at approximately 10:00 a.m. This development is in compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
The Bhayla facility, as of March 31, 2025, had an installed capacity of 852 million units with an available capacity of 600 million units and an actual production of 561 million units, reflecting a capacity utilization of 93.58%. The additional production will increase the installed capacity by 400 million units and the available capacity by 240 million units.
The expansion is funded entirely through internal accruals. The company has made this information available on its website at www.coronaremedies.com.
Corona Remedies Ltd focuses on manufacturing pharmaceutical products, including tablets and capsules. The company is engaged in strategic expansion to enhance its production capabilities and meet market demands.